CNS Pharmaceuticals IncNASDAQ:CNSPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2040
- TODAY'S CHANGE (%)-0.0004 (-0.1957%)
- Bid / Lots0.2100/ 6
- Ask / Lots0.2200/ 2
- Open / Previous Close0.2090 / 0.2044
- Day Range
- 52 Week Range
- Volume134,003
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNSP |
|---|---|---|
| 09:32 ET | 6856 | 0.1998 |
| 09:34 ET | 6625 | 0.196 |
| 09:45 ET | 1720 | 0.195 |
| 09:48 ET | 5600 | 0.195 |
| 09:50 ET | 300 | 0.1998 |
| 09:54 ET | 100 | 0.19745 |
| 10:01 ET | 100 | 0.1987 |
| 10:03 ET | 399 | 0.1975 |
| 10:10 ET | 900 | 0.1998 |
| 10:12 ET | 250 | 0.197904 |
| 10:17 ET | 965 | 0.1979 |
| 10:21 ET | 600 | 0.1999 |
| 10:24 ET | 1000 | 0.1976 |
| 10:39 ET | 500 | 0.1986 |
| 10:42 ET | 1100 | 0.1982 |
| 11:00 ET | 300 | 0.1998 |
| 11:08 ET | 100 | 0.1984 |
| 11:11 ET | 9439 | 0.2 |
| 11:24 ET | 190 | 0.2 |
| 11:26 ET | 1500 | 0.2 |
| 11:29 ET | 6000 | 0.1984 |
| 11:31 ET | 600 | 0.1984 |
| 11:33 ET | 100 | 0.1975 |
| 11:42 ET | 864 | 0.1951 |
| 11:45 ET | 1496 | 0.1974 |
| 11:51 ET | 167 | 0.1955 |
| 12:07 ET | 11300 | 0.1944 |
| 12:12 ET | 100 | 0.1946 |
| 12:21 ET | 300 | 0.1961 |
| 12:25 ET | 400 | 0.1946 |
| 12:38 ET | 1401 | 0.196 |
| 12:39 ET | 2222 | 0.196 |
| 12:41 ET | 700 | 0.1961 |
| 12:43 ET | 666 | 0.1975 |
| 12:45 ET | 24597 | 0.2 |
| 12:52 ET | 7980 | 0.1946 |
| 01:19 ET | 145 | 0.205 |
| 01:28 ET | 4500 | 0.2098 |
| 01:50 ET | 800 | 0.2072 |
| 02:02 ET | 517 | 0.20495 |
| 02:15 ET | 175 | 0.207449 |
| 02:22 ET | 456 | 0.2099 |
| 02:33 ET | 100 | 0.208 |
| 02:40 ET | 100 | 0.2088 |
| 02:42 ET | 143 | 0.2098 |
| 02:51 ET | 1300 | 0.2074 |
| 02:56 ET | 3978 | 0.205 |
| 03:16 ET | 1058 | 0.207 |
| 03:20 ET | 2033 | 0.1912 |
| 03:38 ET | 700 | 0.200989 |
| 03:39 ET | 100 | 0.193 |
| 03:57 ET | 1170 | 0.1974 |
| 03:59 ET | 1009 | 0.204 |
Apr 1, 2024
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements, from 5:01PM ET on Monday Apr 01, 2024 by Dow Jones
5:01PM ET on Monday Apr 01, 2024 by Dow JonesCNS Pharmaceuticals to Present at Two Investor Conferences in April, from 9:07AM ET on Monday Apr 01, 2024 by Dow Jones
9:07AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CNS Pharmaceuticals Inc | 2.2M | 0.0x | --- |
Salarius Pharmaceuticals Inc | 2.2M | -0.1x | --- |
VG Life Sciences Inc | 2.1M | 0.0x | --- |
Galmed Pharmaceuticals Ltd | 2.2M | -0.1x | --- |
Scinai Immunotherapeutics Ltd | 1.9M | -0.1x | --- |
Dermata Therapeutics Inc | 2.0M | -0.1x | --- |
Company Information
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Contact Information
- Headquarters
- 2100 West Loop S Ste 900HOUSTON, TX, United States 77027-3522
- Phone
- ---
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Faith Charles
- Chief Executive Officer, Director
- John Climaco
- Chief Financial Officer
- Christopher Downs
- Chief Science Officer
- Donald Picker
- Chief Medical Officer
- Sandra Silberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-5.76 |
Book Value | $-0.71 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
